Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase.
Dvory-Sobol H, Voitenleitner C, Mabery E, Skurnac T, Lawitz EJ, McHutchison J, Svarovskaia ES, Delaney W, Miller MD, Mo H. Dvory-Sobol H, et al. Among authors: miller md. Antimicrob Agents Chemother. 2014 Nov;58(11):6599-606. doi: 10.1128/AAC.02815-14. Epub 2014 Aug 25. Antimicrob Agents Chemother. 2014. PMID: 25155588 Free PMC article. Clinical Trial.
Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.
Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, Ye L, Niedziela-Majka A, Barnes TL, Novikov N, Chen X, Svarovskaia ES, McColl DJ, White KL, Miller MD. Abram ME, et al. Among authors: miller md. Antimicrob Agents Chemother. 2013 Jun;57(6):2654-63. doi: 10.1128/AAC.02568-12. Epub 2013 Mar 25. Antimicrob Agents Chemother. 2013. PMID: 23529738 Free PMC article.
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.
Svarovskaia ES, Dvory-Sobol H, Parkin N, Hebner C, Gontcharova V, Martin R, Ouyang W, Han B, Xu S, Ku K, Chiu S, Gane E, Jacobson IM, Nelson DR, Lawitz E, Wyles DL, Bekele N, Brainard D, Symonds WT, McHutchison JG, Miller MD, Mo H. Svarovskaia ES, et al. Among authors: miller md. Clin Infect Dis. 2014 Dec 15;59(12):1666-74. doi: 10.1093/cid/ciu697. Epub 2014 Sep 28. Clin Infect Dis. 2014. PMID: 25266287 Free PMC article. Clinical Trial.
L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.
Svarovskaia ES, Gane E, Dvory-Sobol H, Martin R, Doehle B, Hedskog C, Jacobson IM, Nelson DR, Lawitz E, Brainard DM, McHutchison JG, Miller MD, Mo H. Svarovskaia ES, et al. Among authors: miller md. J Infect Dis. 2016 Apr 15;213(8):1240-7. doi: 10.1093/infdis/jiv564. Epub 2015 Nov 24. J Infect Dis. 2016. PMID: 26603202 Free PMC article.
1,102 results